Your browser doesn't support javascript.
loading
Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers.
Romero-Ibarguengoitia, Maria Elena; Rivera-Salinas, Diego; Hernández-Ruíz, Yodira Guadalupe; Armendariz-Vázquez, Ana Gabriela; González-Cantú, Arnulfo; Barco-Flores, Irene Antonieta; González-Facio, Rosalinda; Montelongo-Cruz, Laura Patricia; Del Rio-Parra, Gerardo Francisco; Sanz-Sánchez, Miguel Ángel.
Afiliação
  • Romero-Ibarguengoitia ME; Research Department, Hospital Clínica Nova, San Nicolás de los Garza 66450, NL, Mexico.
  • Rivera-Salinas D; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, NL, Mexico.
  • Hernández-Ruíz YG; Research Department, Hospital Clínica Nova, San Nicolás de los Garza 66450, NL, Mexico.
  • Armendariz-Vázquez AG; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, NL, Mexico.
  • González-Cantú A; Research Department, Hospital Clínica Nova, San Nicolás de los Garza 66450, NL, Mexico.
  • Barco-Flores IA; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, NL, Mexico.
  • González-Facio R; Research Department, Hospital Clínica Nova, San Nicolás de los Garza 66450, NL, Mexico.
  • Montelongo-Cruz LP; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, NL, Mexico.
  • Del Rio-Parra GF; Research Department, Hospital Clínica Nova, San Nicolás de los Garza 66450, NL, Mexico.
  • Sanz-Sánchez MÁ; Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García 66238, NL, Mexico.
Vaccines (Basel) ; 10(3)2022 Mar 03.
Article em En | MEDLINE | ID: mdl-35335024
The efficacy of one dose Ad5-nCoV has been concerning. This study aimed to evaluate the effect of a single dose BNT162b2 in individuals after a completed Ad5-nCoV vaccination regiment compared to a group without this boost measuring SARS-CoV-2 Spike 1−2 IgG antibodies in plasma. This observational study included a subgroup analysis of patients who were immunized with Ad5-nCoV in a northern city of Mexico. During follow-up, some patients self-reported having received a BNT162b2 booster. We report baseline IgG levels, 21−28 days after the Ad5-nCoV dose, three months, and an additional 21−28 days after BNT162b2 (four months after Ad5-nCoV). Seventeen patients, age 40 (16), 52.9% men, were analyzed. We created four groups: G1 and G2 refer to patients without a history of SARS-CoV-2 infection, vaccinated with Ad5-nCoV and Ad5-nCoV/BNT162b2 (n = 4 and n = 6), respectively; G3 and G4 included patients with a history of SARS-CoV-2 infection and immunized with Ad5-nCoV and Ad5-nCoV/BNT162b2 (n = 5 and n = 2), respectively. The Ad5-nCoV/BNT162b2 protocol reported higher antibody titers after 21−28 days. Median (IQR) values were: G1 46.7 (-), G2 1077.5 (1901), G3 1158.5 (2673.5), and G4 2090 (-) (p < 0.05). Headache and pain at injection site were the most frequent adverse reactions associated with Ad5-nCoV (n = 10, 83%) and BNT162b2 (n = 5, 83.3%), respectively. Patients receiving BNT162b2 after Ad5-nCoV had higher SARS-CoV-2 spike 1−2 IgG antibody titers and had no severe adverse reactions.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México País de publicação: Suíça